Axsome Therapeutics Inc (AXSM.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|47||2018||Chairman of the Board, Chief Executive Officer|
|43||2018||Chief Financial Officer|
|2018||Director of Finance, Interim Principal Accounting Officer|
|29||2015||Vice President - Finance|
|32||2014||Senior Director - Operations|
- BRIEF-Axsome Therapeutics Reports Q1 Loss Per Share Of $0.19
- BRIEF-Axsome Therapeutics Announces First Patient Enrolled In Phase 2 Clinical Trial Of AXS-05 In Smoking Cessation
- BRIEF-Axsome Therapeutics Appoints Nick Pizzie, Cpa, Mba, As Chief Financial Officer
- BRIEF-Axsome Therapeutics Reports Q4 Loss Per Share $0.31
- BRIEF-Axsome Therapeutics Says Its CNS Disorder Candidate AXS-09 Met Main Goal Of Phase 1 Trial